Schmielau Jan, Teschendorf Christian, König Matthias, Schmiegel Wolff, Graeven Ullrich
Department of Hematology and Oncology, Sana Kliniken Lübeck, Lübeck, Germany.
Leuk Lymphoma. 2005 Apr;46(4):567-9. doi: 10.1080/10428190400029700.
The use of the proteasome inhibitor bortezomib has been recently introduced into the treatment of relapsed, refractory multiple myeloma (MM). We here demonstrate a case of a patient with IgD MM who was successfully treated with a combination of bortezomib, thalidomide, and dexamethasone. Relapse of the disease occurred following tandem autologous transplantation and was refractory to a salvage therapy consisting of thalidomide, cyclophosphamide, etoposide, and dexamethasone. While the administration of thalidomide was continued, the addition of bortezomib and dexamethasone led to a complete remission after 2 cycles of therapy. The feasibility of this treatment is supported by a recently reported phase I/II trial that used a lower dose of thalidomide in combination with an equal dose of bortezomib. This is the first report of a patient with IgD MM treated accordingly, suggesting that this entity is highly sensitive to the novel therapy.
蛋白酶体抑制剂硼替佐米最近已被用于复发性、难治性多发性骨髓瘤（MM）的治疗。我们在此展示了一例IgD型MM患者，该患者通过硼替佐米、沙利度胺和地塞米松联合治疗获得成功。疾病在串联自体移植后复发，且对由沙利度胺、环磷酰胺、依托泊苷和地塞米松组成的挽救疗法耐药。在继续使用沙利度胺的同时，加用硼替佐米和地塞米松，经过2个周期的治疗后实现了完全缓解。最近报道的一项I/II期试验支持了这种治疗的可行性，该试验使用了较低剂量的沙利度胺并联合等量的硼替佐米。这是首例按此方案治疗的IgD型MM患者的报告，表明该类型对这种新疗法高度敏感。
